Yes, Missling says that “We have not made a final decision” , I think, meaning a final decision about a partner, which is necessary as Xena points out. Negotiating and drafting a detailed agreement with a partner is an involved process, and Anavex needs to carefully protect its proprietary information, intellectual property rights, etc. The requirement that a Japanese partner must be involved may give Japanese companies a bit of leverage. However, if AVXL 2-73 continues to show potential to treat an unmet need, there may be competition among interested Japanese companies to partner up with Anavex especially with the thought that this one thing, Rett, may lead to other things (AD, PDD, and other CNS disease treatments). Japan, I believe has an early access program. If a drug proves to be safe, obtaining some form of approval should not be difficult as long as AVXL 2-73 demonstrates the necessary benefit as well as safety.
Market Data 
Markets 
AI
